Abstract PR008: Docetaxel and the Tumor Targeting Interleukin-12 (IL-12) PDS01ADC in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
Melissa L. Abel(National Institutes of Health), Ravi A. Madan(National Cancer Institute), Jennifer L. Marté(National Cancer Institute), Yo-Ting Tsai(Comprehensive Blood & Cancer Center), Lisa M. Cordes(National Institutes of Health Clinical Center), Amy Hankin(National Institutes of Health), Fatima Karzai(National Institutes of Health), Philip M. Arlen(Dana-Farber Cancer Institute), Megan Hausler(National Institutes of Health), N. Williams(National Institute of Allergy and Infectious Diseases), Renee Donahue(National Institutes of Health), James Gulley(National Institutes of Health), Aanika Warner(Krankenhaus Bethanien), Jeffrey Schlom(National Institutes of Health), James W. Hodge(National Cancer Institute), William D. Figg(National Institutes of Health), Ruchi P. Patel(University of Pennsylvania)
Cited by 0
Related Papers
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
|The Journal of Experimental Medicine|2006|1.7k
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|975
Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes
|Cancer Research|2004|544
External Beam Radiation of Tumors Alters Phenotype of Tumor Cells to Render Them Susceptible to Vaccine-Mediated T-Cell Killing
|Cancer Research|2004|439
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
|Clinical Cancer Research|2018|415